S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   277.20 (+2.08%)
AAPL   114.96 (+2.39%)
MSFT   209.44 (+0.78%)
FB   256.82 (+0.78%)
GOOGL   1,458.66 (+1.36%)
AMZN   3,174.05 (+2.55%)
TSLA   421.20 (+3.40%)
NVDA   521.40 (+1.25%)
BABA   276.01 (+1.81%)
CGC   14.21 (+0.28%)
GE   6.20 (+1.47%)
MU   49.72 (+1.18%)
AMD   79.48 (+1.82%)
T   28.38 (+1.21%)
F   6.69 (+2.76%)
ACB   4.78 (-5.35%)
GILD   62.85 (+0.96%)
NFLX   490.65 (+1.61%)
DIS   125.99 (+1.60%)
BA   166.08 (+6.44%)
BAC   24.09 (+2.55%)
Log in
NASDAQ:CNST

Constellation Pharmaceuticals Stock Forecast, Price & News

$19.71
+0.27 (+1.39 %)
(As of 09/28/2020 04:42 PM ET)
Add
Compare
Today's Range
$18.92
Now: $19.71
$20.09
50-Day Range
$17.62
MA: $22.46
$27.89
52-Week Range
$6.01
Now: $19.71
$59.49
Volume467,860 shs
Average Volume516,321 shs
Market Capitalization$936.23 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Read More
Constellation Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNST
CUSIP21036U206
Phone617-714-0555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$8.23 per share

Profitability

Net Income$-85,550,000.00

Miscellaneous

Employees82
Market Cap$936.23 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$19.71
+0.27 (+1.39 %)
(As of 09/28/2020 04:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

How has Constellation Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CNST shares have decreased by 39.5% and is now trading at $19.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Constellation Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Constellation Pharmaceuticals
.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Constellation Pharmaceuticals
.

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals Inc (NASDAQ:CNST) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.06.
View Constellation Pharmaceuticals' earnings history
.

What price target have analysts set for CNST?

10 Wall Street analysts have issued 1 year target prices for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $75.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $43.56 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals
.

Are investors shorting Constellation Pharmaceuticals?

Constellation Pharmaceuticals saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 3,600,000 shares, a decrease of 15.5% from the August 15th total of 4,260,000 shares. Based on an average daily trading volume, of 668,500 shares, the days-to-cover ratio is currently 5.4 days.
View Constellation Pharmaceuticals' Short Interest
.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO), NVIDIA (NVDA) and AT&T (T).

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the following people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Sr. VP, CFO Treasurer & Sec. (Age 58)
  • Dr. Adrian M. Senderowicz, Sr. VP & Chief Medical Officer (Age 55)
  • Dr. Danny Reinberg Ph.D., Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (7.33%), Vanguard Group Inc. (3.53%), Venrock Management V LLC (3.28%), Regents of The University of California (2.95%), Deerfield Management Company L.P. Series C (1.84%) and Victory Capital Management Inc. (1.82%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals
.

Which major investors are selling Constellation Pharmaceuticals stock?

CNST stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC, Regents of The University of California, Deerfield Management Company L.P. Series C, P.A.W. Capital Corp, Alps Advisors Inc., AQR Capital Management LLC, and Strs Ohio. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents, and Patrick Trojer.
View insider buying and selling activity for Constellation Pharmaceuticals
.

Which major investors are buying Constellation Pharmaceuticals stock?

CNST stock was acquired by a variety of institutional investors in the last quarter, including Venrock Management V LLC, Great Point Partners LLC, Vanguard Group Inc., Jennison Associates LLC, Candriam Luxembourg S.C.A., Goldman Sachs Group Inc., Sofinnova Investments Inc., and Venrock Partners Management V LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals
.

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $19.71.

How big of a company is Constellation Pharmaceuticals?

Constellation Pharmaceuticals has a market capitalization of $936.23 million. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.